ARM makes little difference to cataract surgery outcomes

Article

Patients with age-related maculopathy (ARM) undergoing cataract surgery can expect favourable visual and quality of life outcomes one to three years following surgery, according to the results of a study published in the March issue of Eye.

Patients with age-related maculopathy (ARM) undergoing cataract surgery can expect favourable visual and quality of life outcomes one to three years following surgery, according to the results of a study published in the March issue of Eye.

Jie Jin Wang and colleagues from the University of Sydney and the Westmead Hospital, New South Wales, Australia re-examined patients with and without ARM who had undergone cataract surgery between 2001 and 2003. They tested visual acuity (VA) and assessed visual and health-related quality of life (HRQoL) using standardized questionnaires (VF-14, SF-12). Preoperative co-morbidity data was collected from medical records. Poor surgical outcomes (VA< 6/12; no improvement in VA; lowest quintile of VF-14, SF-12 scores) were compared in subjects with and without ARM.

A total of 454 patients were followed up for a mean period of 2.8 years. Similar numbers of patients in the ARM and non-ARM groups had VA< 6/12, equating to 80.2% and 88.8%, respectively. Preoperative early ARM was associated with a slightly lower mean VF-14 score. Increasing age and preoperative ocular co-morbidities were associated with all poor outcomes measured.

The results of this study suggest that patients with ARM who have undergone cataract surgery can expect reasonable outcomes over three years.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.